Navigation Links
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
Date:9/18/2013

ditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection and Stivarga® (regorafenib) tablets being the only approved products from which we may obtain revenue; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; supply of Nexavar, Stivarga or Kyprolis; market acceptance and the rate of adoption of Nexavar, Stivarga and Kyprolis; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, Stivarga or Kyprolis; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; and product liability risks; and other risks and uncertainties discussed in Onyx's filings with the Securities and Exchange Commission (the "Commission"), including the "Risk Factors" sections of Onyx's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as the tender offer documents to be filed by Arena Acquisition Corporation, a wholly owned subsidiary of Amgen, and the Solicitation/Recommendation Statement to be filed by Onyx. Onyx undertakes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. 

Contacts:

Amgen
Ashleigh Koss, 805-313-
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
2. Amgen To Participate At Citis 8th Annual Biotech Conference
3. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
4. Amgen to Highlight New Data at Upcoming ESC Congress 2013
5. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
6. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
9. Amgen Announces Webcast of 2013 Second Quarter Financial Results
10. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7 Novartis Pharmaceuticals Corporation today announced the ... 0.5 mg daily, a first-line oral treatment for ... by the US Food and Drug Administration (FDA) ... with MS and healthcare professionals seeking information about ...
... Privigen®, the first and only 10% ... is effective and well tolerated in patients with ... presented today at the XIVth Meeting of the ... Privigen offers significant protection against infection. ...
Cached Medicine Technology:Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 2Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 3Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 4Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 5Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 6Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 7Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... Patrick Johnston, whose work has transformed cancer care in ... the European Academy of Cancer Sciences., The Academy, which ... of highly distinguished oncologists and cancer researchers which aims ... in Europe. , Professor Johnston, whose leadership has seen ... bottom of the UK league table to near the ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...
... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...
... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...
... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...
... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...
Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:A Mother's Love Overcomes Poverty's Effect on Health 2Health News:A Mother's Love Overcomes Poverty's Effect on Health 3Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:National registry to track eosinophilic disorders 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: